Full Press Release Details
Issue of Equity on Exercise of Warrants
London, New York, 22 October 2020
- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology
company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted
and issued 285,714 ordinary shares of 3 pence each ("New Ordinary Shares") credited as fully paid at a price of
35 pence per share in respect of the exercise of 285,714 warrants held by a warrant holder.
Application has been made for the 285,714
New Ordinary Shares to be admitted to trading on AIM ("Admission"), and dealings are expected to commence on or
around 29 October 2020. The New Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.
In conformity with DTR 5.6.1, the Company
notifies that as at the date of this announcement, it has a single class of shares in issue being Ordinary Shares and that following
the issue of the New Ordinary Shares to be issued in connection with the exercise of the warrants, the total number of Ordinary
Shares in issue will be 193,512,501. There are no Ordinary Shares held in treasury. Each Ordinary Share entitles the holder to
a single vote at general meetings of the Company.
The figure of 193,512,501 Ordinary Shares
may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will
determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual
listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules
to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly
initiating phase 2 studies with orally administered foralumab for Crohn's Disease and nasally administered foralumab for
progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in
the world. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's
Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb,
a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
This announcement contains inside information
for the purposes of Article 7 of EU Regulation 596/2014. The person who arranged the release of this information is Keeren Shah,
Finance Director of Tiziana.
For further enquiries:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder
Cairn Financial Advisers LLP (Nominated
Liam Murray / Jo Turner +44 (0)20 7213
Optiva Securities Limited (Broker)
Robert Emmet +44 (0)20 3981 4173
RedChip Companies Inc.
001 407 - 491 - 4498